Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Older Adults

LSD for Older Adults

16 papers and 1 clinical trial exploring lsd as a treatment for older adults.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
IndicationApproximately 300 million adults worldwide struggle with depression, many of whom are older adults.

Older Adults

Psychedelic research involving older adults is gaining traction, highlighting the potential therapeutic benefits of compounds such as psilocybin and MDMA. Recent studies suggest promising safety profiles and efficacy, paving the way for future clinical applications in this demographic.

Full Older Adults profile

Academic Research

16 papers
Open Accessindividual

Age moderates the relationship between psychedelics use and mental health in naturalistic settings

This cross-sectional survey (n=1,088) found that age significantly moderates the relationship between lifetime psychedelic use and mental health, with classic psychedelics such as psilocybin being associated with lower depression and anxiety in younger adults, but these benefits diminish with age and even reverse for anxiety in older participants.

Published
March 10, 2026
Journal
Research Square
Authors
Gregorio, G. D., Basset, S., Manmohan, H., Nixon, W. C., Pogaku, A., Zhou, J., Sanderson, D. J., Lengieza, M. L., Bocchio, M.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Open Accessindividual

Naturalistic psychedelic use and changes in depressive symptoms

This longitudinal observational study (n=12,345) of U.S. residents found that naturalistic psychedelic use (n=505, 4.1% of participants) was associated with modest increases in depressive symptoms, particularly when occurring in 'risk contexts' characterised by negative mindset and lack of psychological support, with challenging psychedelic experiences mediating this relationship and suggesting that unsupervised psychedelic use may not be generally therapeutic and could worsen depression under certain circumstances.

Published
December 1, 2025
Journal
Journal of Affective Disorders
Authors
Simonsson, O., Hendricks, P. S., Swords, C. M., Osika, W., Goldberg, S. B.
Paywallindividual

Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial

In a multicentre phase 2b randomised placebo‑controlled trial of 198 adults with moderate to severe GAD, a single dose of MM120 (lysergide D‑tartrate) produced a dose‑dependent reduction in HAM‑A scores at 4 weeks, with 100 µg and 200 µg showing significant improvements versus placebo (least‑squares mean differences −5.0 and −6.0 points, respectively). Adverse events were dose‑related—most commonly visual perceptual changes and nausea—supporting the efficacy and informing dose selection for phase 3 trials.

Published
October 21, 2025
Journal
JAMA
Authors
Robison, R., Barrow, R., Conant, C., Foster, E., Freedman, J. M., Jacobsen, P. L., Karas, S. M., Karlin, D. R., Solomon, T. M., Wernli, M. H., Fava, M. F., Jemisen, J.
Open Accessindividual

Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults A Randomized Clinical Trial

In a 6‑week, multicentre, double‑blind randomised phase 2A trial of 53 adults with moderate–severe ADHD, twice‑weekly low‑dose LSD (20 μg) was physically safe and psychologically well tolerated. However, LSD did not reduce ADHD symptoms more than placebo on the AISRS.

Published
June 1, 2025
Journal
JAMA Psychiatry
Authors
Mueller, L., de Jesus, N. M. S., Schmid, Y., Müller, F., Becker, A. M., Klaiber, A., Straumann, I., Luethi, D., Haijen, E. C. H. M., Hurks, P. P. M., Kuypers, K. P. C., Liechti, M. E.
Open Accessindividual

Hallucinogen use among young adults ages 19-30 in the United States: Changes from 2018 to 2021

In a longitudinal US cohort of 11,304 young adults aged 19–30 surveyed 2018–2021, past‑year LSD use remained stable (≈3.7% to 4.2%) while non‑LSD hallucinogen use (e.g. psilocybin) roughly doubled from 3.4% to 6.6%. Use was more likely among males, white participants and those from higher socio‑economic backgrounds, and less likely among Black participants and those without a college‑educated parent.

Published
June 7, 2023
Journal
Addiction
Authors
Keyes, K. M., Patrick, M. E.

Clinical Trials

1 trial
CompletedPhase I

A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years

Phase I double-blind, placebo-controlled, randomised study (n=48) of very low-dose LSD (5, 10, 20 µg) or placebo given six times over 21 days in healthy volunteers aged 55–75.

Started
June 29, 2015
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04421105

Explore further

Search all LSD papers Search all Older Adults trials Full LSD profile Full Older Adults profile